Prospective evaluation of detection of circulating tumor DNA (ctDNA) to predict recurrence after definitive therapy of localized stage lung cancer (PREDICT)

Prospective evaluation of detection of circulating tumor DNA (ctDNA) to predict recurrence after definitive therapy of localized stage lung cancer (PREDICT) - PREDICT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016416

Enrollment

180

Registered

2019-04-08

Start date

2019-03-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer nsclc and sclc

Interventions

Group 1: Based on the ctDNA results, the study population will be analyzed in 3 arms: 1. ctDNA pre-therapeutically detectable and post-therapeutically not detectable. Group 2: 2. ctDNA pre-therapeuti

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with NSCLC stage I-IVA with planned curative therapy. SCLC stage I-IIIC with planned curative therapy.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Recurence-free survival at 1, 2, 3, 5 years post-therapeutically.	—

Secondary

Measure	Time frame
Overall-survival	—

Countries

Germany

Contacts

Public ContactMartin Faehling

Klinik für Kardiologie und PneumologieKlinikum Esslingen

m.faehling@klinikum-esslingen.de071131032402

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026